P1125: CELESTIMO: A PHASE III TRIAL EVALUATING THE EFFICACY AND SAFETY OF MOSUNETUZUMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

ABSTRACT:

SUBMITTER: Nastoupil L 

PROVIDER: S-EPMC9430742 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature